Welcome to our dedicated page for Galmed Pharmaceu news (Ticker: GLMD), a resource for investors and traders seeking the latest updates and insights on Galmed Pharmaceu stock.
Galmed Pharmaceuticals Ltd. develops Aramchol, an SCD1 inhibitor drug candidate, as a clinical-stage biopharmaceutical company focused on liver disease, cardiometabolic disease and gastrointestinal oncology therapeutics. Company updates frequently cover Aramchol development in NASH/MASH and fibrosis, combination approaches, patent activity, scientific presentations and efforts to expand the pipeline into oncology and cardiometabolic indications.
Recent developments also include collaborations and formulation work tied to Aramchol-based research, including human organoid models for cardiac fibrosis, preclinical evaluation in metastatic brain cancers and brain-penetrating delivery approaches for CNS-related applications. Other recurring corporate news includes annual-report filings, shareholder communications and Nasdaq listing compliance matters.
Galmed Pharmaceuticals (NASDAQ: GLMD) signed a definitive agreement to acquire Colospan, creating a GI-focused medtech and biopharmaceutical platform targeting a $6 billion colorectal surgery market.
Colospan’s CG-100 intraluminal bypass device holds FDA Breakthrough Device status, is CE marked, in a U.S. pivotal IDE trial, and planned for EU launch in H2 2026. Deal consideration totals $4.5 million plus a planned $6 million EU launch investment, with closing expected in Q2 2026.
Galmed (NASDAQ: GLMD) and Tissue Dynamics reported preclinical data on a combination of Aramchol Meglumine and a selective PPARα agonist in human cardiac organoids.
The combo identified a previously unknown metabolic pathway in cardiac fibrosis and reduced fibrotic burden about fourfold (p<0.001), while preserving cardiac muscle and metabolic function. A new patent was filed and IND-enabling preparations are underway.
Galmed (NASDAQ: GLMD) reported Phase 1 pharmacokinetics results for its oral formulation Aramchol meglumine (AM) in healthy subjects (Study AM-001).
Single 400mg and 200mg AM doses showed approximately 5-fold and 3-fold higher Aramchol bioavailability versus 300mg Aramchol free acid (AA) tablets. The 400mg AM once-daily dose is intended to match exposure from AA 300mg twice daily.
According to Galmed, this transition may enable GMP clinical batch production, extend Aramchol IP protection, potentially cut drug cost of goods by ~50%, and improve patient convenience and compliance in future MASH and GI oncology uses.
Galmed (NASDAQ: GLMD) and Tissue Dynamics announced a collaboration to build a human-centered chronic cardiac fibrosis platform to accelerate Aramchol-based therapeutics. The platform uses vascularized, multichambered cardiac organoids with embedded metabolic sensors, AI, and automation to test >20,000 organoids in parallel.
The model targets post-MI remodeling and HFpEF, links SCD1-driven lipid metabolism to fibrosis and impaired repair, and aims to support preclinical evaluation of dosing, combinations, and disease-stage interventions.
Galmed (NASDAQ: GLMD) announced on April 14, 2026 a research collaboration with Tel Aviv University (via Ramot) to evaluate its brain-penetrant SCD1 inhibitor Aramchol as a targeted therapy for p53-deficient metastatic brain cancers. The collaboration will use TAU's 3D in vitro and in vivo models to validate Aramchol's efficacy and support ongoing clinical work at Virginia Commonwealth University's Massey Cancer Center.
Galmed (NASDAQ: GLMD) announced a breakthrough brain-penetrating formulation of its SCD1 inhibitor Aramchol, co-developed with Barcode Nanotech, using lipid nanoparticles designed for subcutaneous delivery across the blood–brain barrier.
In vitro data show dose-dependent reduction of α-synuclein aggregation; Galmed plans a PoC Ph1b/2 study in Parkinson disease in H2 2026, subject to regulatory advice.
Galmed Pharmaceuticals (Nasdaq: GLMD) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. SEC on March 31, 2026. The report is available on the SEC website and Galmed's investor relations site, and copies are available on request.
Galmed remains a clinical-stage company focused on Aramchol for NASH, exploring combination therapies and oncological and cardiometabolic indications. The filing includes forward-looking statements and risk disclosures, including regulatory, clinical, financing and regional security risks.
Galmed Pharmaceuticals (Nasdaq: GLMD) received a Nasdaq notice dated January 29, 2026, informing the company that its ordinary shares are below the $1.00 minimum bid price required by Nasdaq Listing Rule 5550(a)(2).
The company has a 180-calendar-day compliance period from January 29, 2026, through July 28, 2026, to regain compliance by achieving a closing bid of at least $1.00 for ten consecutive business days. Trading of GLMD shares continues on the Nasdaq Capital Market during the cure period, and failure to regain compliance could lead to delisting procedures.
Galmed (NASDAQ: GLMD) announced a late-breaking abstract presentation at HEP-DART 2025 for Aramchol titled "Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma." The poster will be presented on December 9, 2025 at 3:00 PM HST. Galmed reports preclinical data showing SCD1 inhibition augments regorafenib (Stivarga) activity via ATM-AMPK-autophagy signaling, providing translational rationale for a planned Phase 1/2 trial of Aramchol plus regorafenib in HCC and other GI cancers with enrollment planned to start in 2026. Galmed also plans a Phase 2 dose-expansion cohort to evaluate adding metformin to the combination.
Galmed (NASDAQ: GLMD) announced a new use patent in South Korea covering a combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of non-alcoholic steatohepatitis (NASH/MASH) and liver fibrosis.
The company says this grant joins earlier patents in the United States, Europe, Canada and other jurisdictions and extends Aramchol's patent protection worldwide, with U.S. protection noted through July 2042. Galmed describes Aramchol as a Phase 3–ready candidate with reported fibrosis improvement and favorable safety and tolerability, positioning it for combination therapy development in MASH.